| scholarly article | Q13442814 |
| P50 | author | Ton Fang | Q57041747 |
| P Nigel Leigh | Q64857298 | ||
| Ahmad Al Khleifat | Q87885845 | ||
| Pamela Shaw | Q20716854 | ||
| Daniel Stahl | Q37369733 | ||
| Ammar Al-Chalabi | Q39362985 | ||
| P2093 | author name string | Caroline Murphy | |
| Carolyn Young | |||
| Claudia Lazo La Torre | |||
| Uk-Mnd LicalS | |||
| P2860 | cites work | Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis | Q48116439 |
| The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). | Q53535985 | ||
| Amyotrophic lateral sclerosis in an urban setting | Q57499018 | ||
| Amyotrophic lateral sclerosis severity scale | Q69617955 | ||
| The Measurement of Observer Agreement for Categorical Data | Q26778373 | ||
| El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis | Q29619074 | ||
| Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial | Q34648924 | ||
| A proposed staging system for amyotrophic lateral sclerosis | Q35776890 | ||
| A clinical tool for predicting survival in ALS. | Q37471676 | ||
| Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials | Q39264219 | ||
| Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study. | Q40729676 | ||
| Rehabilitation techniques for patients with amyotrophic lateral sclerosis | Q43418200 | ||
| Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis | Q43718510 | ||
| An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole | Q44177987 | ||
| Socioeconomic costs of amyotrophic lateral sclerosis according to staging system | Q44624576 | ||
| Xaliproden in amyotrophic lateral sclerosis: early clinical trials | Q44941859 | ||
| The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. | Q46373510 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3-4 | |
| P921 | main subject | amyotrophic lateral sclerosis | Q206901 |
| P304 | page(s) | 227-232 | |
| P577 | publication date | 2017-01-05 | |
| P1433 | published in | Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | Q23928840 |
| P1476 | title | Comparison of the King's and MiToS staging systems for ALS. | |
| P478 | volume | 18 |
| Q91660593 | A standard operating procedure for King's ALS clinical staging |
| Q57158112 | ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS |
| Q56531747 | Amyotrophic lateral sclerosis |
| Q92378722 | Applying the D50 disease progression model to gray and white matter pathology in amyotrophic lateral sclerosis |
| Q64228443 | Clinical Measures of Bulbar Dysfunction in ALS |
| Q55443790 | Clinical Staging of Amyotrophic Lateral Sclerosis in Chinese Patients. |
| Q104503062 | Improving clinical trial outcomes in amyotrophic lateral sclerosis |
| Q47621875 | Longitudinal diffusion imaging across the C9orf72 clinical spectrum. |
| Q47352723 | Longitudinal structural changes in ALS: a three time-point imaging study of white and gray matter degeneration |
| Q64075393 | Tracking a Fast-Moving Disease: Longitudinal Markers, Monitoring, and Clinical Trial Endpoints in ALS |
| Q30234813 | What causes amyotrophic lateral sclerosis? |
Search more.